These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23370678)

  • 1. Oral glutamine supplementation improves intestinal permeability dysfunction in a murine acute graft-vs.-host disease model.
    Noth R; Häsler R; Stüber E; Ellrichmann M; Schäfer H; Geismann C; Hampe J; Bewig B; Wedel T; Böttner M; Schreiber S; Rosenstiel P; Arlt A
    Am J Physiol Gastrointest Liver Physiol; 2013 Apr; 304(7):G646-54. PubMed ID: 23370678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model.
    Noth R; Lange-Grumfeld J; Stüber E; Kruse ML; Ellrichmann M; Häsler R; Hampe J; Bewig B; Rosenstiel P; Schreiber S; Arlt A
    BMC Gastroenterol; 2011 Oct; 11():109. PubMed ID: 21977944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy.
    Stüber E; Büschenfeld A; von Freier A; Arendt T; Fölsch UR
    Gut; 1999 Aug; 45(2):229-35. PubMed ID: 10403735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice.
    Ohta M; Tateishi K; Kanai F; Ueha S; Guleng B; Washida M; Tanaka Y; Ijichi H; Ikenoue T; Sata M; Sudo T; Shiina S; Kawabe T; Matsushima K; Omata M
    Eur J Immunol; 2005 Jul; 35(7):2210-21. PubMed ID: 15971269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats.
    Beutheu S; Ouelaa W; Guérin C; Belmonte L; Aziz M; Tennoune N; Bôle-Feysot C; Galas L; Déchelotte P; Coëffier M
    Clin Nutr; 2014 Aug; 33(4):694-701. PubMed ID: 24095638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential cytokine expression in acute and chronic murine graft-versus-host-disease.
    Allen RD; Staley TA; Sidman CL
    Eur J Immunol; 1993 Feb; 23(2):333-7. PubMed ID: 8436168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of tissue transglutaminase (transglutaminase type II) for the intestinal manifestations of murine semi-allogenic graft-versus-host disease.
    Stüber E; Noth R; Dirks M; Arendt T; Fölsch U
    J Autoimmun; 2002 Feb; 18(1):1-8. PubMed ID: 11869041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host intestinal intraepithelial gamma delta T lymphocytes present during acute graft-versus-host disease in mice may contribute to the development of enteropathy.
    Sakai T; Ohara-Inagaki K; Tsuzuki T; Yoshikai Y
    Eur J Immunol; 1995 Jan; 25(1):87-91. PubMed ID: 7843257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine graft-versus-host disease in an F1-hybrid model using IFN-gamma gene knockout donors.
    Ellison CA; Fischer JM; HayGlass KT; Gartner JG
    J Immunol; 1998 Jul; 161(2):631-40. PubMed ID: 9670937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity.
    Ilan Y; Ohana M; Pappo O; Margalit M; Lalazar G; Engelhardt D; Rabbani E; Nagler A
    Transplantation; 2007 Feb; 83(4):458-67. PubMed ID: 17318079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
    Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
    J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
    Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
    Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
    Shankar G; Bryson JS; Jennings CD; Morris PE; Cohen DA
    Am J Respir Cell Mol Biol; 1998 Feb; 18(2):235-42. PubMed ID: 9476911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
    Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
    Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
    Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
    Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of KRN7000 on induced graft-vs-host disease.
    Morecki S; Panigrahi S; Pizov G; Yacovlev E; Gelfand Y; Eizik O; Slavin S
    Exp Hematol; 2004 Jul; 32(7):630-7. PubMed ID: 15246159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DBA/2J and DBA/2Ha lymphocytes differ in their ability to induce graft-vs-host disease.
    Fast LD
    J Immunol; 1989 Oct; 143(8):2489-93. PubMed ID: 2794505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.